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Pathogenetic mechanisms, new drugs, and old
problems in idiopathic recurrent pericarditis:
comment on the article by Picco et al
To the Editor:
We read with interest the recent article by Picco et al
in which the authors present case reports of 3 children with
recurrent pericarditis who were treated, during flares, with the
interleukin-1 (IL-1) receptor antagonist anakinra, with im-
mediate response (1). High-dose nonsteroidal antiinflamma-
tory drugs (NSAIDs) are recommended as the mainstay of
therapy for recurrent pericarditis (aspirin 2–4 gm/day, indo-
methacin 75–225 mg/day, ibuprofen 1,200–3,200 mg/day) (2,3).
Although corticosteroids should be restricted in patients with
pericarditis, when they are indicated, high doses have been
recommended (2,3). However, we have demonstrated that
the lower doses commonly used by rheumatologists are safer
and more effective (4). The results of previous studies have
demonstrated that colchicine can reduce the recurrence of
pericarditis (5–7); in a randomized controlled study, colchicine
had reduced recurrences by half at 18 months (7). Picco and
colleagues showed that idiopathic recurrent pericarditis can be
successfully treated with anakinra (1), and we agree that this
agent can represent a novel therapeutic tool, although its role
needs to be more clearly defined. Anakinra should probably be
reserved for patients who do not tolerate other therapies, and
it also could be considered an alternative to corticosteroids in
patients whose disease does not respond to high-dose NSAIDs
plus colchicine and in the rare instances when the required
dosage and duration of steroid treatment are unacceptably
high. For anakinra, however, Picco et al describe dependence
similar to that observed in patients taking steroids, and
NSAIDs and colchicine probably remain the best option for
avoiding this dependence.
As discussed by Picco and colleagues, idiopathic recur-
rent pericarditis shares several features with autoinflammatory
diseases, such as recurrent episodes of apparently unprovoked
serosal inflammation, leukocytosis, and familial occurrence
(the last of which our group has described as occurring in 10%
of relatives of pericarditis patients [8]). We have also found
that the most frequent mutations linked to familial Mediter-
ranean fever were absent in these patients (6). Dysregulation
of IL-1 may be very important in this condition, and we agree
that recurrent “idiopathic” or “autoreactive” pericarditis (2)
may indeed be an as-yet unidentified autoinflammatory dis-
ease in a subset of patients.
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Reply
To the Editor:
We thank Dr. Brucato and colleagues for their com-
ments and are glad that they agree with our suggestion that
IL-1 inhibition could represent a therapeutic option in some
patients with idiopathic recurrent pericarditis. In this respect,
the recent availability of more potent IL-1 inhibitors is also of
particular interest. The long-acting interleukin-1 inhibitor
rilonacept (interleukin-1 Trap) has proven effective in the
treatment of familial cold-induced autoinflammatory syn-
drome (1). Moreover, in a recent study on the efficacy of a
monoclonal antibody against IL-1 (canakinumab) in children
with systemic juvenile idiopathic arthritis, our group observed
that, in patients who showed a notable response to the
treatment, a single dose of the antibody induced a remission
lasting for several weeks or months (2). Similar long-lasting
remissions after a single injection of canakinumab have been
observed in patients with autoinflammatory syndromes, such
as cryopyrin-associated periodic syndrome (3). It could be
hypothesized that patients with idiopathic recurrent pericardi-
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